Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060614 | 0.84 | ALDH1A1 (0.46) | SMN1; SMN2RAB9AALDH1A1HTTLMNA | |
| SCHEMBL23455573 | 0.83 | MAPT (0.45) | SMN1; SMN2RAB9AALDH1A1HTTLMNA | |
| SCHEMBL2060680 | 0.83 | CHRNB4 (0.40) | ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL6368673 | 0.82 | HTT (0.44) | SMN1; SMN2RAB9AALDH1A1USP2HTT | |
| SCHEMBL27313536 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2RAB9AALDH1A1LMNAKMT2A | |
| SCHEMBL10183487 | 0.77 | HTT (0.69) | SMN1; SMN2RAB9AALDH1A1USP2HTT | |
| SCHEMBL2060579 | 0.77 | ALDH1A1 (0.46) | SMN1; SMN2RAB9AALDH1A1LMNANPC1 | |
| SCHEMBL2915985 | 0.76 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL2061015 | 0.75 | CHRNB4 (0.46) | SMN1; SMN2RAB9AALDH1A1HTTLMNA | |
| SCHEMBL2060805 | 0.75 | NOTUM (0.48) | SMN1; SMN2RAB9AALDH1A1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020661-A1 | Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal | GAMMILL RONALD B (US) | 2005-01-27 | — | — | US | disclosed |
| US-6821977-B2 | SUBSTITUTED 1H-(INDOLE-2- CARBOXAMIDES AND 6H-THIENO(2,3-B)PYRROLE-5-CARBOXAMIDES USEFUL FOR INHIBITING GLYCOGEN PHOSPHORYLASE IN A MAMMAL | PFIZER, INC. | 2004-11-23 | — | — | US | disclosed |
| US-20030199553-A1 | Antidiabetic agents | GAMMILL RONALD B (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003072570-A1 | ANTIDIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-1340500-A1 | Antidiabetic agents | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199553-A1 | Antidiabetic agents | GPR119, IRS1, INSR | SMN1; SMN2 2393/4885RAB9A 735/4885ALDH1A1 1021/4885 |
| US-20050020661-A1 | Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal | PYGM, PYGL, IRS1 | SMN1; SMN2 3622/4885RAB9A 2493/4885ALDH1A1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.